Barinthus Biotherapeutics plc
BRNS
Price:
$0.671
Market Cap:
$27.41M
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV)....[Read more]
Industry
Biotechnology
IPO Date
2021-04-30
Stock Exchange
NASDAQ
Ticker
BRNS
PE Ratio
[-0.52]
ROE
[-63.87%]
Current Ratio
[6.05]
Dividend Yield
[0%]
Enterprise Value
[-28771394.00]
Dividend History
The ROE as of June 2026 (TTM) for Barinthus Biotherapeutics plc (BRNS) is -63.87%
According to Barinthus Biotherapeutics plc’s latest financial reports and current stock price. The company's current ROE is -63.87%. This represents a change of 318.02% compared to the average of -15.28% of the last 4 quarters.
Barinthus Biotherapeutics plc (BRNS) Historical ROE (quarterly & annually)
How has BRNS ROE performed in the past?
The mean historical ROE of Barinthus Biotherapeutics plc over the last ten years is 56.98%. The current -63.87% ROE has changed -212.09% with respect to the historical average. Over the past ten years (40 quarters), BRNS's ROE was at its highest in in the December 2020 quarter at 295.51%. The ROE was at its lowest in in the June 2025 quarter at -20.63%.
Average
56.98%
Median
-20.17%
Minimum
-89.73%
Maximum
500.45%
Barinthus Biotherapeutics plc (BRNS) ROE by Quarter and Year
Discovering the peaks and valleys of Barinthus Biotherapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 441.90%
Maximum Annual ROE = 500.45%
Minimum Annual Increase = -1885.50%
Minimum Annual ROE = -89.73%
| Year | ROE | Change |
|---|---|---|
| 2025 | -89.73% | 91.03% |
| 2024 | -46.97% | 19.61% |
| 2023 | -39.27% | -1885.50% |
| 2022 | 2.20% | -110.90% |
| 2021 | -20.17% | -104.03% |
| 2020 | 500.45% | 441.90% |
Barinthus Biotherapeutics plc (BRNS) Average ROE
How has BRNS ROE performed in the past?
The current ROE of Barinthus Biotherapeutics plc (BRNS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-58.65%
5-year avg
-38.79%
10-year avg
56.98%
Barinthus Biotherapeutics plc (BRNS) ROE vs. Peers
How is BRNS’s ROE compared to its peers?
Barinthus Biotherapeutics plc’s ROE is greater than CEL-SCI Corporation (-221.50%), less than Karyopharm Therapeutics Inc. (73.11%), greater than INmune Bio, Inc. (-170.86%), greater than Senti Biosciences, Inc. (-503.79%), less than Mersana Therapeutics, Inc. (183.15%), greater than Aligos Therapeutics, Inc. (-139.47%), greater than OnKure Therapeutics, Inc. (-61.02%), greater than Medicus Pharma Ltd. Common Stock (-4086.31%), greater than Tempest Therapeutics, Inc. (-729.89%), greater than Kezar Life Sciences, Inc. (-58.35%),
| Company | ROE | Market cap |
|---|---|---|
| -221.50% | $7.42M | |
| 73.11% | $215.30M | |
| -170.86% | $32.97M | |
| -503.79% | $25.24M | |
| 183.15% | $145.36M | |
| -139.47% | $32.67M | |
| -61.02% | $57.43M | |
| -4086.31% | $7.44M | |
| -729.89% | $5.60M | |
| -58.35% | $53.86M |
Build a custom stock screener for Barinthus Biotherapeutics plc (BRNS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Barinthus Biotherapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Barinthus Biotherapeutics plc (BRNS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Barinthus Biotherapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Barinthus Biotherapeutics plc's ROE?
How is the ROE calculated for Barinthus Biotherapeutics plc (BRNS)?
What is the highest ROE for Barinthus Biotherapeutics plc (BRNS)?
What is the 3-year average ROE for Barinthus Biotherapeutics plc (BRNS)?
What is the 5-year average ROE for Barinthus Biotherapeutics plc (BRNS)?
How does the current ROE for Barinthus Biotherapeutics plc (BRNS) compare to its historical average?